NASDAQ:ARCT - Arcturus Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcturus Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.67 -0.28 (-2.34 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$11.35Now: $11.67▼$12.2150-Day Range$9.88MA: $11.14▼$12.4252-Week Range$4.26Now: $11.67▼$15.50Volume34,644 shsAverage Volume74,906 shsMarket Capitalization$176.68 millionP/E RatioN/ADividend YieldN/ABeta2.46 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Arcturus Therapeutics Ltd., an RNA medicines company, focuses on treatment of liver and respiratory diseases. The company's pipeline of RNA therapeutics include programs pursuing rare diseases, hepatitis B, non-alcoholic steatohepatitis, cystic fibrosis, and vaccines. The company owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers, which are covered by its patent portfolio, including 152 patents and patent applications issued in the United States, Europe, Japan, China, and internationally. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARCT Previous Symbol CUSIPN/A CIK1410997 Webhttp://www.arcturusrx.com/ Phone858-900-2660Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$15.75 million Price / Sales11.22 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book9.19Profitability EPS (Most Recent Fiscal Year)($2.16) Net Income$-21,780,000.00 Net Margins-63.05% Return on Equity-160.16% Return on Assets-36.14%Miscellaneous Employees72 Outstanding Shares15,140,000Market Cap$176.68 million Next Earnings Date3/16/2020 (Estimated) OptionableOptionable Receive ARCT News and Ratings via Email Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:ARCT Rates by TradingView Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions What is Arcturus Therapeutics' stock symbol? Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT." How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Ltd (NASDAQ:ARCT) released its earnings results on Thursday, November, 7th. The biotechnology company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.32. The biotechnology company earned $3.32 million during the quarter, compared to analyst estimates of $7.60 million. Arcturus Therapeutics had a negative net margin of 63.05% and a negative return on equity of 160.16%. View Arcturus Therapeutics' Earnings History. When is Arcturus Therapeutics' next earnings date? Arcturus Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Arcturus Therapeutics. What price target have analysts set for ARCT? 5 Wall Street analysts have issued twelve-month target prices for Arcturus Therapeutics' stock. Their forecasts range from $18.00 to $18.00. On average, they anticipate Arcturus Therapeutics' share price to reach $18.00 in the next twelve months. This suggests a possible upside of 54.2% from the stock's current price. View Analyst Price Targets for Arcturus Therapeutics. What is the consensus analysts' recommendation for Arcturus Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcturus Therapeutics. Has Arcturus Therapeutics been receiving favorable news coverage? Media headlines about ARCT stock have been trending somewhat negative on Saturday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Arcturus Therapeutics earned a daily sentiment score of -1.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Arcturus Therapeutics. Are investors shorting Arcturus Therapeutics? Arcturus Therapeutics saw a increase in short interest in the month of December. As of December 13th, there was short interest totalling 178,000 shares, an increase of 83.3% from the November 28th total of 97,100 shares. Based on an average daily volume of 70,400 shares, the days-to-cover ratio is currently 2.5 days. Approximately 2.4% of the company's shares are short sold. View Arcturus Therapeutics' Current Options Chain. Who are some of Arcturus Therapeutics' key competitors? Some companies that are related to Arcturus Therapeutics include Collegium Pharmaceutical (COLL), Akero Therapeutics (AKRO), Emisphere Technologies (EMIS), TherapeuticsMD (TXMD), DiaMedica Therapeutics (DMCAF), Flexion Therapeutics (FLXN), Frequency Therapeutics (FREQ), Omeros (OMER), Cara Therapeutics (CARA), Vectura Group (VEGPF), Urogen Pharma (URGN), AC Immune (ACIU), Kadmon (KDMN), Morphic (MORF) and MacroGenics (MGNX). What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Opko Health (OPK), Energy Transfer LP Unit (ET), Corbus Pharmaceuticals (CRBP), KLA (KLAC), Abeona Therapeutics (ABEO), Amicus Therapeutics (FOLD), Inovio Pharmaceuticals (INO), Terravia (TVIAQ), Corcept Therapeutics (CORT) and Exelixis (EXEL). Who are Arcturus Therapeutics' key executives? Arcturus Therapeutics' management team includes the folowing people: Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 47)Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 40)Mr. Andrew H. Sassine, CFO & Director (Age 55)Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance ManagementKeith C. Kummerfeld CPA, VP of Fin. & Corp. Controller How do I buy shares of Arcturus Therapeutics? Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Arcturus Therapeutics' stock price today? One share of ARCT stock can currently be purchased for approximately $11.67. How big of a company is Arcturus Therapeutics? Arcturus Therapeutics has a market capitalization of $176.68 million and generates $15.75 million in revenue each year. The biotechnology company earns $-21,780,000.00 in net income (profit) each year or ($2.16) on an earnings per share basis. Arcturus Therapeutics employs 72 workers across the globe.View Additional Information About Arcturus Therapeutics. What is Arcturus Therapeutics' official website? The official website for Arcturus Therapeutics is http://www.arcturusrx.com/. How can I contact Arcturus Therapeutics? Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected] MarketBeat Community Rating for Arcturus Therapeutics (NASDAQ ARCT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 339 (Vote Outperform)Underperform Votes: 309 (Vote Underperform)Total Votes: 648MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Vote "Outperform" if you believe ARCT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARCT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: How big is the FinTech market?
